Harvard University Genomic Medicines Fund
Supports research at Harvard advancing genome editing and genomic medicine from discovery through clinical application for disease prevention and treatment.
Funder: Harvard University
Due Dates (Anticipated): March 2027 (Full application deadline, projected)
Funding Amounts: Up to $200,000 per year (direct costs) for 2 years; maximum $400,000 total direct costs per award (plus indirect costs at federal rate)
Summary: Supports research at Harvard University advancing genome editing and genomic medicine, from discovery to clinical application for disease prevention and treatment.
Key Information: Eligibility restricted to Harvard-employed PIs; Editas Genomics holds first right to negotiate licensing of resulting patents.
Description
The Harvard University Genomic Medicines Fund provides critical resources to support innovative research projects in genome editing and genomic medicine at Harvard University. The Fund aims to accelerate advances in technologies and approaches that are relevant to the prevention or treatment of human diseases. Projects may range from early-stage discovery and exploratory studies to those addressing translational gaps or nearing clinical implementation and commercialization. Proposals are evaluated for intellectual merit, innovation, and their potential impact on the research community and clinical practice.
